XTalks

OCTOBER 18, 2022

Global medical device company Nevro Corp has received US Food and Drug Administration (FDA) approval for the Senza HFX iQ spinal cord stimulation (SCS) system for the treatment of long-term or chronic pain. HFX iQ is designed to improve the consistency of pain relief and is the only SCS system that truly personalizes care,” said D.

FDA Approval 98

FDA Approval Big Data Life Science Clinical Trials 98

pharmaphorum

OCTOBER 12, 2021

Bumetanide’s potential was discovered by analysing data on more than 1,300 FDA-approved drugs derived from brain tissue samples, laboratory experiments involving animal and human cells, and human population studies.

Gene Expression 111

Gene Expression Drugs FDA Approval Gene 111

pharmaphorum

FEBRUARY 1, 2022

His research focuses on the development of big data machine learning for tracking the health of complex systems. He has worked on Visensia, the world’s first FDA-approved multivariate patient monitoring system, and the SEND system, which is now used to monitor 20,000 patients each month in the NHS.

Clinical Trials 104

Clinical Trials Clinical Trials Trials Engineer 104

pharmaphorum

SEPTEMBER 16, 2022

The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection. AI relies on data. Speed and cost-effectiveness are one thing, but without good data to act upon, results are meaningless. AI drug discovery in immunology today, and tomorrow.

Development 135

Development Research Drugs Clinical Trials 135

XTalks

MAY 9, 2024

We also invented four proprietary antibody technologies, including our DuoBody® bispecific technology which is the backbone of four FDA-approved bispecifics and over ten in development. Tahi Ahmadi: Two key areas where we anticipate breakthroughs are technological advancements and new modalities.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

The Pharma Data

JULY 12, 2021

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. “Academic labs and pharmaceutical and? biotech companies?have

Drugs 52

Drugs Gene Expression Big Data Gene 52

The Pharma Data

OCTOBER 25, 2020

“We are pleased to continue pursuing additional neuroscience opportunities with BXCL501, targeting agitation associated with delirium, a fifth potential indication for this candidate and a condition for which there is no FDA-approved treatment,” commented Vimal Mehta, Chief Executive Officer of BTI. BioXcel Therapeutics, Inc.

Trials 52

Trials Production FDA Approval Development 52